Standard screening tools were designed for other purposes. They were never optimized to find early fatty liver — which is precisely the window where reversal is most achievable.
Fatty liver is one of the most common conditions in medicine and one of the most commonly missed — not because clinicians overlook it, but because the standard screening tools were designed to answer different questions.
This is not a criticism of the clinicians who order these tests. ALT, AST, and ultrasound-based elastography are legitimate, evidence-based tools. They simply were not optimized to detect fat accumulation in its early, most reversible stage. Understanding their limitations is the first step toward asking better questions about your own health.
A research study published in 2026 found that patients with confirmed fatty liver showed adverse patterns across six distinct biomarker domains — GGT, triglycerides, insulin resistance, LDL cholesterol, HDL cholesterol, and inflammatory markers — yet each shift individually fell short of standard alarm thresholds. The risk was real. The pattern was there. The single-marker approach simply could not see it.
These enzymes rise when liver cells are damaged and release their contents into the bloodstream. They are designed to flag active cell injury — not the accumulation of fat that precedes injury. Research from the NASH Clinical Research Network shows that 30–40% of people with biopsy-confirmed fatty liver have entirely normal ALT and AST values. A normal result is not a clean bill of health for the liver.
Source: NASH Clinical Research Network; multiple NCS publications on noninvasive NAFLD screening.
Vibration-controlled transient elastography (FibroScan) measures liver stiffness as a surrogate for fibrosis. It is a valuable tool for staging advanced disease and monitoring fibrosis progression. However, its sensitivity decreases substantially at low fibrosis scores — precisely the early-stage disease where fat is accumulating but structural damage has not yet begun. By the time elastography reliably detects a problem, the simplest reversal window has typically passed.
Source: Multiple systematic reviews on VCTE/elastography sensitivity at F0–F1 fibrosis stages.
Fatty liver does not announce itself through a single abnormal value. It develops through the convergence of metabolic, inflammatory, and hepatic signals — each subclinical when viewed alone. A triglyceride level that is elevated but within range. A GGT that is climbing but not yet flagged. An insulin resistance index that suggests early dysfunction but doesn't appear on a standard panel at all. Together these signals describe a pattern. Separately, they are invisible.
A 2026 meta-analysis of 52 studies found that patients with fatty liver showed systematically adverse biomarker profiles compared to those without the condition — across multiple domains simultaneously.
Each individual shift fell below typical alarm thresholds. Together, they describe a body under significant and measurable cardiometabolic strain. This is the pattern that comprehensive, multi-system assessment is designed to detect.
The HDL reduction shown in red is particularly important: HDL cholesterol is protective. Its decline in fatty liver patients compounds the atherogenic lipid pattern driven by rising triglycerides and LDL.
Source: Zhong J et al. Risk-associated and clinically informative biomarkers for cardiovascular risk stratification in MASLD. Am J Prev Cardiol. 2026;26:101415.
A comprehensive cardiometabolic evaluation considers how multiple biological systems interact — rather than flagging isolated out-of-range values. The domains below represent the full picture that single-panel approaches cannot capture.
GGT in combination with other markers provides early hepatic fat signaling. The Fatty Liver Index — incorporating GGT, triglycerides, BMI, and waist circumference — is one of the most validated non-invasive tools for early fatty liver detection and cardiovascular risk stratification.
Fasting insulin, HOMA-IR, and triglyceride-glucose index together characterize the degree of insulin resistance driving hepatic fat accumulation. These markers are rarely included in standard annual panels despite their strong predictive value for early metabolic dysfunction.
Total lipid values tell an incomplete story. The pattern of elevated triglycerides, reduced HDL, elevated small dense LDL, and blood pressure at or above 130/85 mmHg together define the atherogenic milieu that MASLD generates — and that standard cholesterol panels often underrepresent.
High-sensitivity CRP reflects the low-grade chronic inflammation that fatty liver generates and that in turn accelerates cardiovascular disease. MASLD patients show average hs-CRP levels more than 1 mg/L higher than non-steatotic controls — a meaningful difference that persists even in early-stage disease.
The FIB-4 index — derived from age, AST, ALT, and platelet count — provides a non-invasive estimate of fibrosis burden. At a threshold of 1.30, it is associated with a more than twofold increase in cardiovascular risk, making it a valuable bridging marker between hepatic and cardiovascular assessment.
Thyroid function influences hepatic lipid clearance, fatty acid oxidation, and metabolic rate. Subclinical hypothyroidism accelerates fat accumulation even when TSH remains within conventional reference ranges. In perimenopausal women, estradiol and progesterone dynamics add an additional layer of metabolic complexity that standard panels do not assess.
Fatty liver is one of the most reversible metabolic conditions when caught in the right window. The same comprehensive approach that finds it is the approach that measures its resolution.
1. Zhong J, Zhao Y, He H, Lan Y, Cai Z. Risk-associated and clinically informative biomarkers for cardiovascular risk stratification in metabolic dysfunction-associated steatotic liver disease. Am J Prev Cardiol. 2026;26:101415.
2. NASH Clinical Research Network. Prevalence of normal ALT in biopsy-proven NAFLD. Referenced in multiple NCS publications on noninvasive screening limitations.
3. Multiple systematic reviews on vibration-controlled transient elastography (VCTE) sensitivity at F0–F1 fibrosis stages in MASLD.